Clinical trial
A Randomized Phase III Study of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) With or Without Concurrent Chemotherapy Followed by Consolidation Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG-P02
NCT03308552 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase III Study of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) With or Without Concurrent Chemotherapy Followed by Consolidation Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG-P02
- Lead sponsor
- Chinese Academy of Medical Sciences
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- December 1, 2017
- Completion date
- August 30, 2021
- Enrollment
- 164 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.